Skip to main content
SpringerLink
Log in

Sitagliptin: a guide to its use in type 2 diabetes mellitus

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67(4): 587–97

    Article  PubMed  CAS  Google Scholar 

  2. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360–72

    Article  PubMed  CAS  Google Scholar 

  3. Deacon CF, Hoist JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 2006; 38(5-6): 831–44

    Article  PubMed  CAS  Google Scholar 

  4. Januvia™ (sitagliptin phosphate) tablets: full prescribing information. Whitehouse Station (NJ): Merck & Co., Inc., 2006 Oct

  5. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 Nov; 91(11): 4612–9

    Article  PubMed  CAS  Google Scholar 

  6. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006 Aug; 46(8): 876–86

    Article  PubMed  CAS  Google Scholar 

  7. Merck & Co. Januvia™ approved in the European Union for the treatment of type 2 diabetes [media release]. 2007 Mar 27

  8. Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV inhibitor [abstract no. PIII-60]. Clin Pharmacol Ther 2006 Feb 1;79(2): P75

    Article  Google Scholar 

  9. Hanefeld M, Herman G, Mickel C, et al. Effect of MK-0431, a dipeptidyl peptidase IV inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes [abstract no. 791]. Diabetologia 2005 Aug; 48Suppl. 1: A287

    Google Scholar 

  10. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007 Jan; 61(1): 171–80

    Article  PubMed  CAS  Google Scholar 

  11. Nonaka K, Kakikawa T, Sato A, et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4), in Japanese patients with type 2 diabetes [abstract no. 0038]. Diabetologia 2006 Sep; 49 Suppl. 1: 25–6

    Google Scholar 

  12. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006 Sep 26; 49: 2564–71

    Article  PubMed  CAS  Google Scholar 

  13. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 Dec; 29(12): 2632–7

    Article  PubMed  CAS  Google Scholar 

  14. Scott R, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI) [abstract no. 1997-PO]. Diabetes 2006 Jun; 55 Suppl. 1: A462

    Google Scholar 

  15. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 Oct; 28(10): 1556–68

    Article  PubMed  CAS  Google Scholar 

  16. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and P-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007 Mar; 9(2): 186–93

    Article  PubMed  CAS  Google Scholar 

  17. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 Dec; 29(12): 2638–43

    Article  PubMed  CAS  Google Scholar 

  18. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007 Mar; 9(2): 194–205

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sitagliptin: a guide to its use in type 2 diabetes mellitus. Drugs Ther. Perspect 23, 5–8 (2007). https://doi.org/10.2165/00042310-200723060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723060-00002

Search

Navigation